A Phase 2b/3, double-blind, randomized, placebo-controlled 48-week safety and efficacy trial of ANAVEX2-73 for the treatment of early Alzheimer’s disease

Occurring Dates
Participant Duration
12 months
State of study
New South Wales
South Australia
Western Australia

Anavex Life Sciences is seeking volunteers to participate in a new clinical trial for people with mild Alzheimer's disease. ANAVEX2-73 is a small molecule that has shown in research studies to improve mental activities that are involved in learning, remembering and using general daily knowledge. These results are associated with ANAVEX2-73 possibly having protective properties on the brain neurons (brain nerve cells) that are usually damaged in Alzheimer’s disease. It is thought that ANAVEX2-73 acts by attaching to and activating specific proteins called “survival receptors” and this may enable ANAVEX2-73 to modify the disease.

Participation in this study will involve taking a daily oral tablet (ANAVEX2-73 or placebo) and visiting a research centre for 8 study appointments over a 48 week period. To be eligible to participate, participants must be:

  • Between 60 and 85 years of age
  • Have a diagnosis of mild Alzheimer's disease
  • Have a study partner able attend study appointments
  • Can read and converse in English
Further information

If you think this sounds interesting and would like to know more, please register your details at www.anavexaustralia.com or phone (02) 8437 7355.

The Frankston (VIC) trial site can be contacted on (03) 9770 1579 and the NeuroCentrix (VIC) trial site can be contacted on (03) 9546 0009 or at [email protected].

A full list of study locations is available at: https://clinicaltrials.gov/ct2/show/NCT03790709.

This research has been approved by St Vincents Hospital (Melbourne) Ethics Committee (Project Number: 123/18).

Full Name
A/Prof Stephen Macfarlane
Phone Number
(02) 8437 7355